MDGL FY 2024 Earnings — Madrigal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

MDGLMadrigal Pharmaceuticals, Inc.

$10B

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$180M

Gross Profit

$174M96.5% margin

Operating Income

-$498M-276.4% margin

Net Income

-$466M-258.6% margin

EPS (Diluted)

$-21.90

Cash Flow

Operating Cash Flow

-$456M

Free Cash Flow

-$457M

Stock-Based Comp.

$80M

Balance Sheet

Total Assets

$1.0B

Total Liabilities

$288M

Stockholders' Equity

$754M

Cash & Equivalents

$100M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$180M	$0	—
Gross Profit	$174M	$0	—
Operating Income	-$498M	-$380M	-30.8%
Net Income	-$466M	-$374M	-24.7%